|
Molecular properties generated using the CDK |
No information available. |
Summary of Clinical Use ![]() |
Proguanil is used in combination with atovaquone in both the treatment of uncomplicated malaria caused by P. falciparum and in malaria prophylaxis [1]. Proguanil is on the World Health Organisation's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019). |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Cycloguanil, the active metabolite of proguanil, is an inhibitor of Plasmodium dihydrofolate reductase (DHFR). Proguanil has a different mechanism of action when used in combination with atovaquone, with the prodrug having synergistic activity, leading to enhanced collapse of the mitochondrial membrane potential [2]. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) |